Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels
Open Access
- 26 July 2005
- journal article
- Published by Springer Nature in Thrombosis Journal
- Vol. 3 (1) , 10
Abstract
Background: To be fully activated platelets are dependent on two positive feedback loops; the formation of thromboxane A2 by cyclooxygenase in the platelets and the release of ADP. We wanted to evaluate the effect of aspirin on platelet function in patients with acute coronary syndromes and we hypothesized that increased levels of ADP in patients with acute coronary syndromes could contribute to aspirin resistance. Methods: Platelet activity in 135 patients admitted for chest pain was assessed with PFA-100. An epinephrine-collagen cartridge (EPI-COLL) was used for the detection of aspirin resistance together with an ADP-collagen cartridge (ADP-COLL). ADP was measured with hplc from antecubital vein samples. Three subgroups were compared: chest pain with no sign of cardiac disease (NCD), NonST-elevation myocardial infarction (NSTEMI) and STEMI. Results: Platelet activation was increased for the STEMI group compared NCD. Aspirin resistance defined as <193 sec in EPI-COLL was 9.7 % in NCD, and increased to 26.0 % (n.s.) in NSTEMI and 83.3 % (p < 0.001) in STEMI. Chronic aspirin treatment significantly reduced platelet aggregation in NCD and NSTEMI, but it had no effect in STEMI. Plasma levels of ADP were markedly increased in STEMI (905 ± 721 nmol/l, p < 0.01), but not in NSTEMI (317 ± 245), compared to NCD (334 ± 271, mean ± SD). ADP levels correlated with increased platelet activity measured with ADP-COLL (r = -0.30, p < 0.05). Aspirin resistant patients (EPI-COLL < 193 sec) had higher ADP levels compared to aspirin responders (734 ± 807 vs. 282 ± 187 nmol/l, mean ± SD, p < 0.05). Conclusion: Platelets are activated and aspirin resistance is more frequent in STEMI, probably due to a general activation of platelets. ADP levels are increased in STEMI and correlates with platelet activation. Increased levels of ADP could be one reason for increased platelet activity and aspirin resistance.Keywords
This publication has 28 references indexed in Scilit:
- The Importance of von Willebrand Factor Level and Heart Rate Changes in Acute Coronary Syndromes: A Comparison with Chronic Ischemic ConditionsAngiology, 2003
- Erythrocyte and the Regulation of Human Skeletal Muscle Blood Flow and Oxygen DeliveryCirculation Research, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Towards a definition of aspirin resistance: a typological approachPlatelets, 2002
- Effects of P2Y 1 and P2Y 12 receptor antagonists on platelet aggregation induced by different agonists in human whole bloodPlatelets, 2001
- Constitutive Release of ATP and Evidence for Major Contribution of Ecto-nucleotide Pyrophosphatase and Nucleoside Diphosphokinase to Extracellular Nucleotide ConcentrationsJournal of Biological Chemistry, 2000
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Aspirin therapy: Optimized platelet inhibition with different loading and maintenance dosesAmerican Heart Journal, 1995
- EFFECTS OF INTERMITTENT TREATMENT WITH ASPIRIN ON THROMBOXANE AND PROSTACYCLIN FORMATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1988
- Shortened bleeding time in acute myocardial infarction and its relation to platelet mass.BMJ, 1985